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On-site mortality in crush syndrome remains high due to lack of effective drugs based on
definite diagnosis. Anisodamine (Ani) is widely used in China for treatment of shock, and
activation of α7 nicotinic acetylcholine receptor (α7nAChR) mediates such antishock
effect. The present work was designed to test whether activation of α7nAChR with
Ani decreased mortality in crush syndrome shortly after decompression. Sprague-
Dawley rats and C57BL/6 mice with crush syndrome were injected with Ani (20 mg/kg
and 28 mg/kg respectively, i.p.) 30 min before decompression. Survival time, serum
potassium, insulin, and glucose levels were observed shortly after decompression.
Involvement of α7nAChR was verified with methyllycaconitine (selective α7nAChR
antagonist) and PNU282987 (selective α7nAChR agonist), or in α7nAChR knockout
mice. Effect of Ani was also appraised in C2C12 myotubes. Ani reduced mortality
and serum potassium and enhanced insulin sensitivity shortly after decompression in
animals with crush syndrome, and PNU282987 exerted similar effects. Such effects
were counteracted by methyllycaconitine or in α7nAChR knockout mice. Mortality and
serum potassium in rats with hyperkalemia were also reduced by Ani. Phosphorylation
of Na/K-ATPase was enhanced by Ani in C2C12 myotubes. Inhibition of tyrosine kinase
on insulin receptor, phosphoinositide 3-kinase, mammalian target of rapamycin, signal
transducer and activator of transcription 3, and Na/K-ATPase counteracted the effect of
Ani on extracellular potassium. These findings demonstrated that activation of α7nAChR
could decrease on-site mortality in crush syndrome, at least in part based on the decline
of serum potassium through insulin signaling-Na/K-ATPase pathway.
Keywords: α7 nicotinic acetylcholine receptor, crush syndrome, mortality, hyperkalemia, insulin sensitivity,
Na/K-ATPase
INTRODUCTION
Crush injury is defined as compression of the extremities or other parts of the body, resulting
in muscle swelling and/or neurological disturbances in the affected areas of the body (Oda et al.,
1997). Based on crush injury, crush syndrome is characterized by systemic symptoms due to
rhabdomyolysis including acute kidney injury, hypovolemic shock, and metabolic disorders (e.g.,
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hyperkalemia), etc. (Better, 1997; Oda et al., 1997; Bywaters and
Beall, 1998; Slater and Mullins, 1998; Sever et al., 2015), which
appears to be common in disasters, wars, and acts of terrorism.
Crush syndrome in violent earthquakes, with an incidence about
2∼15%, is the most frequent cause of death, apart from trauma
(Ukai, 1997). Up to 20% crush victims died of cardiac arrest
caused by hyperkalemia or hypovolemic shock in a short time
(Ashkenazi et al., 2005). However, safe and effective drugs to
reduce on-site mortality in crush syndrome are clinically vacant,
due to lack of definite diagnosis (Sever and Vanholder, 2013).
Anisodamine (Ani) is a belladonna alkaloid isolated from
the Chinese medicinal herb Scopolia tangutica Maxim of the
Solanaceae family indigenous to Tibet. It is used clinically to
improve blood flow in circulatory disorders such as septic
shock and disseminated intravascular coagulation. Our previous
studies found that activation of α7 nicotinic acetylcholine
(ACh) receptor (α7nAChR) is involved in the antishock effect
of Ani (Liu et al., 2009). We speculated that Ani could
reduce mortality in crush syndrome shortly after decompression
through activation of α7nAChR. A series of experiments on
crush syndrome in rats and α7nAChR knockout (α7−/−) mice
were designed to test this hypothesis. As known, insulin can
promote entrance of potassium into cells. The effect of insulin
on serum potassium has been attributed to activation of Na/K-
ATPase (Chibalin et al., 2001; Al-Khalili et al., 2004; Benziane
and Chibalin, 2008). Chronic exposure to nicotine could enhance
insulin sensitivity via α7nAChR (Wang et al., 2011; Xu et al.,
2012). We speculated that activation of α7nAChR with Ani
could decrease serum potassium through elevation of insulin
sensitivity.
The present work was designed to test the effectiveness of
activating α7nAChR on reduction of on-site mortality in crush
syndrome, and to demonstrate the signaling pathway involved.
Here, we show for the first time that activation of α7nAChR could
decrease on-site mortality in crush syndrome. Decline of serum
potassium by activating α7nAChR is intimately linked to insulin
signaling-Na/K-ATPase pathway.
MATERIALS AND METHODS
Animals and Reagents
Sprague-Dawley rats (230∼270 g) and C57BL/6 mice (25∼30 g)
were purchased from Sino-British SIPPR/BK Laboratory
Animals (Shanghai, China). α7−/− mice were generated and
genotyped by PCR analysis as described previously (Liu et al.,
2009). Animals were housed at 22◦C under a 12/12 light
schedule (on: 08:00), with free access to tap water and standard
rat chow. All experimental procedures were in accordance
with institutional animal care guidelines and approved by
ethics committee of Second Military Medical University. Ani
(Ani hydrochloride: C17H24NO4) was purchased from Fu-Ma
Chemical and Engineering Company (Hangzhou, China).
Mecamylamine hydrochloride, methyllycaconitine (MLA)
citrate, hexamethonium chloride, ACh chloride, nicotine,
PNU282987 (PNU), static, ouabain octahydrate, potassium
chloride, and antibody against α7nAChR were purchased from
Sigma–Aldrich (St. Louis, MO, USA). HNMPA-(AM)3 and
antibody against p-Na/K-ATPase were purchased from Santa
Cruz Biotechnology (Dallas, TX, USA). Antibody against insulin
receptor, Alexa-488-labeled and Cy3-labeled second antibodies,
and DAPI were purchased from Abcam (Cambridge, MA, USA).
LY 294002 and rapamycin were purchased from Merck Millipore
(Darmstadt, Germany).
Preparation of Crush Syndrome Models
Rats were anesthetized with a combination of ketamine
(10 mg/kg, i.p.) and diazepam (0.1 mg/kg, i.p.) after an overnight
fast, while mice were anesthetized with a combination of
ketamine (15 mg/kg, i.p.) and diazepam (0.15 mg/kg, i.p.) after 6-
h fast. The animals were fixed in prone position, with hind limbs
(4.5 and 2 cm from the ankles up for rats and mice respectively)
compressed by 20 kg weights for 5 h. The mortality was 70–80%
at 24 h after decompression.
Cell Culture and Differentiation
Mouse C2C12 myoblasts were kindly provided by Stem Cell
Bank, Chinese Academy of Sciences and cultured with DMEM
supplemented with 10% FBS, 2 mmol/L glutamate, 15 mmol/L
HEPES, 100 IU/ml penicillin, and 100 mg/ml streptomycin in
95% O2 and 5% CO2. To obtain fully differentiated myotubes,
FBS was removed from cell culture at 70% confluence, and cells
were incubated in a medium containing 2% horse serum for 4
additional days.
Serum Biochemical Assays
Serum creatine kinase (CK), CK isoenzyme-MB (CK-MB),
blood urea nitrogen (BUN), serum creatinine (Scr), K+,
Na+, Cl−, and glucose levels in rats or mice and extracellular
K+ and glucose levels in cultured C2C12 myoblasts were
measured with an autoanalyzer (Beckman Autoanalyzer;
Beckman Instruments, Fullerton, CA, USA). Rats and mice
serum insulin levels were determined by ELISA according to
the manufacturer’s instructions (Shibayagi, Gunma, Japan).
The homeostasis model assessment of insulin resistance
(HOMA-IR) index was calculated according to the following
formula: HOMA-IR = fasting serum insulin (mIU/L) × fasting
serum glucose (mmol/L)/22.5. The quantitative insulin
sensitivity check index (QUICKI) was calculated using the
original formula as the inverse log sum of fasting serum
insulin in mIU/L and fasting serum glucose in mg/dl.
QUICKI = 1/[log(fasting serum glucose) + log(fasting serum
insulin)].
Immunofluorescence
C2C12 cell cultures were carried out directly on glass coverslips
overnight at 37◦C. Cells were rinsed with PBS, fixed with 4
% paraformaldehyde for 15 min at room temperature, and
then rinsed with PBS twice before blocked with 5% BSA
in PBS with Tween 20 for 30 min. Cells were incubated
with primary antibodies against α7nAChR, insulin receptor,
or p-Na/K-ATPase for 2 h at 37◦C. Subsequently, cells were
washed three times for 15 min and incubated with Alexa-488
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FIGURE 1 | Effect of Ani on mortality and serum biochemicals in rats with crush syndrome. Ani (20 mg/kg, i.p.) was administrated 30 min before (Ani-pre) or
1 h after (Ani-post) decompression. Blood samples were collected at 6 h after decompression. Ani prolonged survival time after decompression (A). Serum CK,
CK-MB, BUN, Scr, and K+ levels were significantly reduced by Ani (B–F). Ani had no effect on serum Na+ and Cl− levels (G,H). N = 20 per group. ∗P < 0.05,
∗∗P < 0.01, ∗∗∗P < 0.001 vs. control. Power = 0.90, 1.00, 1.00, 1.00, 1.00, 1.00, 0.11, and 0.13 for (A–H) respectively.
or Cy3-labeled second antibodies for 1 h at 37◦C. Nuclei were
labeled with DAPI for 5 min. After rinsed, glass coverslips
were mounted on glass slides and the cells were visualized
under confocal laser scanning microscope (Park et al., 2014; Tan
et al., 2014). Eight independent fields were acquired from each
coverslip. Measurements were performed as follows: integrated
optical density (IOD) and total fluorescent area (TFA) in each
image was recorded using the Image-Pro Plus 6.0 software
(Media Cybernetics, Bethesda, MD, USA). Mean optical density
(MOD)= IOD/TFA.
Experimental Protocols
Experiment 1: Effect of Ani on Mortality and Serum
Biochemicals in Rats with Crush Syndrome
Rats were randomly divided into four groups (n = 20 per
group): (1) normal: rats received normal saline (i.p.); (2) control:
rats received normal saline (i.p.); (3) Ani-pre: rats received Ani
(20 mg/kg, i.p.) at 30 min before decompression; (4) Ani-post:
rats received Ani (20 mg/kg, i.p.) at 1 h after decompression.
Crush syndrome models were established in groups 2–4. Blood
samples of all the rats were collected from orbital venous sinus
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FIGURE 2 | Involvement of α7nAChR in the effect of Ani on mortality and serum K+ in mice with crush syndrome and effect of Ani on mortality and
serum K+ in rats with hyperkalemia. Ani (28 mg/kg) or PNU (4 mg/kg) was administrated i.p. at 30 min before decompression in mice with crush syndrome, and
MLA (10 mg/kg, i.p.) was given 30 min earlier. Blood samples were collected at 6 h after decompression. Ani and PNU prolonged survival time (n = 15 per group)
and decreased serum K+ level (n = 6 per group) in C57BL/6 mice after decompression, and MLA significantly counteracted such beneficial effects of Ani (A,C). Ani
prolonged survival time (n = 18 per group) and decreased serum K+ level (n = 6 per group) in WT mice for α7nAChR after decompression, which was abolished in
α7−/− mice (B,D). Ani (20 mg/kg, i.p.) was administrated 30 min before injection of KCl (750 mg/kg, i.p.), and blood samples were collected 30 min after KCl
injection. Ani prolonged survival time and decreased serum K+ level in rats with hyperkalemia (n = 18 per group, E,F). ∗P < 0.05, ∗∗P < 0.01 vs. control. #P < 0.05
vs. Ani. Power = 0.60, 0.62, 0.97, 1.00, 0.84, and 0.70 for (A–F) respectively.
at 6 h after decompression, and serum CK, CK-MB, BUN, Scr,
K+, Na+, Cl−, insulin, and glucose levels were measured. Survival
time was monitored for 24 h after decompression.
Experiment 2: Involvement of α7nAChR in the Effect
of Ani on Mortality, Serum K+, and Insulin Sensitivity
in Mice with Crush Syndrome
C57BL/6 mice were randomly divided into five groups (n = 15
per group): (1) control: mice received normal saline (i.p.); (2) Ani
(28 mg/kg); (3) MLA (10 mg/kg); (4) Ani (28 mg/kg) + MLA
(10 mg/kg); (5) PNU (4 mg/kg). Crush syndrome models were
established. Ani or PNU was given i.p. at 30 min before
decompression, and MLA was given i.p. 30 min earlier. Survival
time was monitored for 24 h after decompression. Crush
syndrome models were established in another five groups of
C57BL/6 mice (n = 6 per group) as listed above. Blood samples
were collected from vena cava at 6 h after decompression, and
serum K+, insulin, and glucose levels were measured, as well as
in a “normal” group. In another set of experiments, normal saline
or Ani (28 mg/kg) was given i.p. to α7−/− mice and wild-type
(WT) controls at 30 min before decompression. Survival time was
monitored for 24 h after decompression (n = 18 per group), and
serum K+, insulin, and glucose levels were measured at 6 h after
decompression (n= 6 per group).
Experiment 3: Effect of Ani on Mortality and Serum
K+ in Rats with Hyperkalemia
Rats were randomly divided into two groups (n= 18 per group),
receiving normal saline (i.p.) or Ani (20 mg/kg, i.p.), and KCl
(750 mg/kg, i.p.) was given 30 min later. Blood samples were
collected from orbital venous sinus at 30 min after KCl injection
and from heart for those just died, and serum K+ level was
measured. Survival time was monitored for 24 h after KCl
injection.
Frontiers in Pharmacology | www.frontiersin.org 4 March 2016 | Volume 7 | Article 79
fphar-07-00079 March 28, 2016 Time: 18:40 # 5
Fan et al. α7nAChR and Crush Syndrome
FIGURE 3 | Effect of Ani on insulin sensitivity in rats with crush
syndrome. Ani (20 mg/kg, i.p.) was administrated 30 min before
decompression. Blood samples were collected at 6 h after decompression.
Ani decreased serum insulin (A), but had no significant effect on glucose (B) in
rats after decompression. Ani improved insulin sensitivity, reflected by
decreased HOMA-IR index (C) and increased QUICKI (D). N = 20 per group.
∗P < 0.05, ∗∗P < 0.01 vs. normal. #P < 0.05 vs. control. Power = 1.00 for
(A–D).
Experiment 4: Involvement of α7nAChR in the Effect
of Ani on Extracellular K+ In Vitro
Myotubes were pretreated for 30 min with Ani (500 µg/ml), ACh
(100 µmol/L), Ani (500 µg/ml) + ACh (100 µmol/L), nicotine
(0.01–10 µmol/L), or PNU (0.01–10 µmol/L) prior to exposure
to KCl (5 mmol/L), and extracellular K+ and glucose levels were
measured 6 h later. In another set of experiments, myotubes
were pretreated for 1 h with mecamylamine (10 µmol/L),
MLA (10 µmol/L), or hexamethonium (10 µmol/L), and then
for 30 min with Ani (500 µg/ml) + ACh (100 µmol/L) or
nicotine (1 µmol/L) prior to exposure to KCl (5 mmol/L),
and extracellular K+ and glucose levels were measured 6 h
later.
Experiment 5: Influence of HNMPA-(AM)3 on the
Effect of Ani on Na/K-ATPase Phosphorylation
In Vitro
In these experiments, myotubes were divided into five
groups: (1) normal; (2) control; (3) Ani (500 µg/ml) + ACh
(100 µmol/L); (4) HNMPA-(AM)3 (200 µmol/L); (5) Ani
(500 µg/ml) + ACh (100 µmol/L) + HNMPA-(AM)3
(200 µmol/L). Myotubes were pretreated for 1 h with
HNMPA-(AM)3, and then for 30 min with Ani + ACh
prior to exposure to KCl (5 mmol/L). Phosphorylation of Na/K-
ATPase was then detected with immunofluorescence staining
and confocal microscopy. Expression of α7nAChR and insulin
receptor was also examined in normal C2C12-differentiated
myotubes with immunofluorescence.
Experiment 6: Influences of Insulin Signaling Blocking
on the Effect of Ani on Extracellular K+ In Vitro
Myotubes were pretreated for 1 h with HNMPA-(AM)3
(200 µmol/L), LY 294002 (10 µmol/L), rapamycin (200 nmol/L),
stattic (10 µmol/L), or ouabain (2 mmol/L), and then for 30 min
with Ani (500 µg/ml) + ACh (100 µmol/L) prior to exposure
to KCl (5 mmol/L), and extracellular K+ and glucose levels were
measured 6 h later.
Statistical Analysis
Data are expressed as mean ± SD. For experiments involving
only two groups, data were analyzed with t-test or t’-test.
For experiments involving more than two groups, data were
analyzed with ANOVA followed by Bonferroni test or Games-
Howell test. Kaplan–Meier analysis, followed by a log-rank test,
was used for survival time analysis. P < 0.05 was considered
statistically significant. Survival rate between two groups were
analyzed with Fisher’s exact test. The size of experimental groups
was determined according to statistical requirement, and power
analysis was performed. Analyses were performed using SPSS
21.0 (SPSS, Inc., Chicago, IL, USA) and PASS 11.0 (NCSS, LLC,
Kaysville, UT, USA).
RESULTS
Effect of Ani on Mortality and Serum
Biochemicals in Rats with Crush
Syndrome
The mortality rate within 24 h was much lower in Ani-
pre and Ani-post groups compared with that in control
group (25 and 55% vs. 75%). Kaplan–Meier analysis revealed
significantly longer survival time in Ani-pre group (log-rank
testing χ2 = 14.35, P = 0.00015) and Ani-post group (log-
rank testing χ2 = 3.70, P = 0.049, Figure 1A) compared
with that in control group. Serum CK, CK-MB, BUN, Scr, and
K+ levels at 6 h after decompression were significantly lower
in Ani treated rats, especially in Ani-pre group (P < 0.01,
Figures 1B–F) compared with that in control group. Treatment
with Ani had no effect on serum Na+ and Cl− levels
(Figures 1G,H).
Ani Decreases Mortality and Serum K+ in
Mice with Crush Syndrome through
Activating α7nAChR
The mortality rate within 24 h was much lower in Ani and PNU
groups compared with that in control group (46.7 and 46.7%
vs. 80%), and much higher in Ani + MLA group compared
with that in Ani group (80.0% vs. 46.7%). Kaplan–Meier analysis
revealed significantly longer survival time in Ani group (log-
rank testing χ2 = 5.80, P = 0.016) and PNU group (log-rank
testing χ2 = 5.37, P = 0.020) compared with that in control
group, and significantly shorter survival time in Ani + MLA
group (log-rank testing χ2 = 4.06, P = 0.044, Figure 2A)
compared with that in Ani group. Serum K+ level at 6 h
after decompression was significantly lower in Ani (−16.4%,
Frontiers in Pharmacology | www.frontiersin.org 5 March 2016 | Volume 7 | Article 79
fphar-07-00079 March 28, 2016 Time: 18:40 # 6
Fan et al. α7nAChR and Crush Syndrome
FIGURE 4 | Involvement of α7nAChR in the effect of Ani on insulin
sensitivity in mice with crush syndrome. Ani (28 mg/kg) or PNU (4 mg/kg)
was administrated i.p. at 30 min before decompression in mice with crush
syndrome, and MLA (10 mg/kg, i.p.) was given 30 min earlier. Blood samples
were collected at 6 h after decompression. Ani and PNU reduced serum
insulin (A) and glucose (C) and HOMA-IR index (E), and elevated QUICKI
(G) in C57BL/6 mice after decompression, and MLA significantly
counteracted the effects of Ani. Ani reduced serum insulin (B) and glucose (D)
and HOMA-IR (F) index, and elevated QUICKI (H) in WT mice for α7nAChR
after decompression, which was abolished in α7−/− mice. N = 6 per group.
∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. control. #P < 0.05, ##P < 0.01,
###P < 0.001 vs. Ani. Power = 1.00, 1.00, 1.00, 0.91, 1.00, 1.00, 1.00, and
1.00 for (A–H) respectively.
P< 0.01) or PNU (−17.2%, P< 0.01) treated rats compared with
that in control group, and significantly higher in Ani + MLA
group compared with that in Ani group(+15.0%, P < 0.05,
Figure 2C). Ani significantly decreased the mortality rate
(−50.0%), prolonged survival time (log-rank testing χ2 = 3.88,
P = 0.049, Figure 2B), and decreased serum K+ level (−7.4%,
P < 0.05, Figure 2D) in WT mice, but had no effect in α7−/−
mice.
Ani Decreases Mortality and Serum K+ in
Rats with Hyperkalemia
Serum K+ was much lower in Ani group compared with that
in control group (−14.7%, P < 0.01, Figure 2E), and the
mortality rate within 24 h was also much lower in Ani-treated
rats compared with that in control rats (50.0% vs. 83.3%, P< 0.05,
Figure 2F). All death occurred within 30 min after KCl injection.
Ani Increases Insulin Sensitivity in
Animals with Crush Syndrome through
Activating α7nAChR
Serum insulin and glucose levels and HOMA-IR were
substantially increased, and QUICKI index was markedly
decreased in rats with crush syndrome compared with normal
rats. Ani treatment at 30 min before decompression significantly
reduced insulin level (−26.5%, P < 0.05, Figure 3A), but had no
effect on glucose level (Figure 3B) in rats with crush syndrome,
indicating a higher insulin sensitivity in Ani treated rats. Ani
reduced HOMA-IR to (−34.6%, P < 0.05, Figure 3C) and
elevated QUICKI index to (+4.8%, P< 0.05, Figure 3D) of those
in control group, supporting that Ani treatment enhances insulin
sensitivity. Treatment with Ani significantly enhanced insulin
sensitivity in mice with crush syndrome, reflected by reduced
serum insulin (P < 0.05), glucose (P < 0.01), and HOMA-IR
(P < 0.05), and elevated QUICKI index (P < 0.05). PNU had
similar effect with Ani. However, MLA attenuated the effect of
Ani on insulin sensitivity, reflected by elevated serum insulin
(+29.5%, P < 0.05, Figure 4A), glucose (+95.6%, P < 0.001,
Figure 4C), and HOMA-IR (+69.8%, P < 0.01, Figure 4E),
and reduced QUICKI index (−7.1%, P < 0.01, Figure 4G). Ani
treatment significantly enhanced insulin sensitivity in WT mice,
reflected by reduced serum insulin, glucose, and HOMA-IR,
and elevated QUICKI index (P < 0.05 for all parameters,
Figures 4B,D,F,H), but had no effect in α7−/− mice.
Ani Decreases Extracellular K+ and
Glucose In Vitro through Indirectly
Activating α7nAChR
Extracellular K+ in cultured myotubes was significantly
decreased by ACh (P < 0.01), which could be strengthened
by Ani (P < 0.05, Figure 5A), but Ani alone had no
effect. Nicotine and PNU decreased extracellular K+ in a
concentration-dependent manner (Figures 5C,I). Pretreatment
with mecamylamine (P < 0.01) or MLA (P < 0.01, Figure 5E),
but not hexamethonium, attenuated the effect of Ani and ACh on
extracellular K+. Pretreatment with MLA (P < 0.01, Figure 5G),
but not hexamethonium, attenuated the effect of nicotine on
extracellular K+. Similar results were obtained for extracellular
glucose (Figures 5B,D,F,H,J).
Ani Increases Na/K-ATPase
Phosphorylation In Vitro Relying on
Insulin Receptor
Ani and ACh significantly increased phosphorylation of Na/K-
ATPase in cultured myotubes (+23.5%, P < 0.05). Pretreatment
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FIGURE 5 | Continued
FIGURE 5 | Continued
Involvement of α7nAChR in the effect of Ani on extracellular K+ in
C2C12 cells. C2C12 myotubes were pretreated for 1 h with mecamylamine
(Mec, 10 µmol/L), MLA (10 µmol/L), or hexamethonium (Hex, 10 µmol/L), and
then for 30 min with Ani (500 µg/ml), ACh (100 µmol/L), Ani (500 µg/ml)+ ACh
(100 µmol/L), nicotine (0.01–10 µmol/L), or PNU282987 (0.01–10 µmol/L)
prior to exposure to KCl (5 mmol/L), and extracellular K+ and glucose levels
were measured 6 h later. Extracellular K+ and glucose in cultured myotubes
were significantly decreased by Ani+ ACh (A,B), nicotine (C,D), and PNU (I,J).
Mec and MLA, but not Hex significantly counteracted the effects of Ani + ACh
(E,F) or nicotine (G,H). N = 8 per group. ∗P < 0.05, ∗∗P < 0.01. Power = 1.00
for (A–J).
with HNMPA-(AM)3 attenuated the effect of Ani and ACh
on Na/K-ATPase phosphorylation (−46.0%, P < 0.001) to a
level that was significantly lower than control group (−33.3%,
Figures 6A,B). α7nAChR and insulin receptor were also
expressed in C2C12-differentiated myotubes (Figures 6C,D).
Ani Decreases Extracellular K+ and
Glucose In Vitro through Insulin
Signaling
Extracellular K+ and glucose in cultured myotubes were
significantly decreased by Ani and ACh. Pretreatment with
HNMPA-(AM)3 or ouabain attenuated the effect of Ani and
ACh on extracellular K+ (P < 0.001 for both drugs) to a
level that was significantly higher than control group (+16.2%
and +14.9% respectively, Figures 7A,I). Pretreatment with
LY 294002, rapamycin, or stattic also attenuated the effect of
Ani and ACh on extracellular K+ (P < 0.001 for all drugs,
Figures 7C,E,G). Pretreatment with HNMPA-(AM)3, LY 294002,
or rapamycin, but not stattic or ouabain attenuated the effect of
Ani and ACh on extracellular glucose (Figures 7B,D,F,H,J).
DISCUSSION
The major findings of the present study include: (i) activation
of α7nAChR with Ani decreases on-site mortality in crush
syndrome; (ii) such effect of activating α7nAChR is partially
due to decline of serum potassium; (iii) Ani decreases serum
potassium through insulin signaling-Na/K-ATPase pathway.
The on-site causes of death in crush syndrome are
cardiac arrest caused by hyperkalemia or hypovolemic shock
caused by bleeding or fluid redistribution (Ashkenazi et al.,
2005). Hemostasis, intravenous fluids supplement, and blood
transfusion are required to treat hypovolemic shock, and for
hyperkalemia with definite diagnosis, calcium gluconate, insulin
with glucose, sodium bicarbonate, or β2 adrenergic receptor
agonist are recommended to reduce serum potassium quickly,
followed by hemodialysis and kayexalate or enema (Gonzalez,
2005; Weisberg, 2008; Sever and Vanholder, 2013). However,
there is no safe and effective drug before definite diagnosis in
hospital. Ani is widely used clinically in China for treatment of
various shocks, especially septic shock with fewer and less severe
adverse effects than atropine (Li et al., 1999). In the present
study, we provided evidences that Ani could decrease on-site
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FIGURE 6 | Influence of HNMPA-(AM)3 (HNMPA) on the effect of Ani on Na/K-ATPase phosphorylation in C2C12 cells. C2C12 myotubes were pretreated
for 1 h with HNMPA (200 µmol/L), and then for 30 min with Ani (500 µg/ml) + ACh (100 µmol/L) prior to exposure to KCl (5 mmol/L). Ani + ACh significantly
increased phosphorylation of Na/K-ATPase in cultured myotubes, and HNMPA attenuated such effect (A,B, scale bar = 30 µm). Both α7nAChR (C, scale
bar = 20 µm) and insulin receptor (D, scale bar = 30 µm) were expressed in C2C12-differentiated myotubes, detected with immunofluorescence staining and
confocal microscopy. N = 6 per group. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. control. ###P < 0.001 vs. ACh + Ani. Power = 1.00.
mortality in rats with crush syndrome, especially administrated
before decompression. Therefore Ani was given shortly before
decompression, KCl injection, or exposure of myotubes to
KCl in all of the following experiments. Our previous studies
showed that Ani benefited septic shock through cholinergic anti-
inflammatory pathway, i.e., indirectly activation of α7nAChR
(Liu et al., 2009). Results of this study demonstrated that the
beneficial effect of Ani on mortality in crush syndrome was also
mediated by activation of α7nAChR, based on the facts that PNU,
selective agonist of α7nAChR, has the similar effect to Ani, but
α7nAChR deficiency or MLA, selective antagonist of α7nAChR,
attenuated such effect of Ani.
Sudden decompression of the crush victims may release
toxic cellular components and electrolytes, such as myoglobin,
creatinine, and potassium, from necrotic muscles into blood
circulation (Santangelo et al., 1982; Noji, 1992). Consistent
with these studies, we observed higher serum potassium and
more severe muscle destruction and renal dysfunction in rats
with crush syndrome. Treatment with Ani could alleviate these
symptoms. However, whether alleviation of the above symptoms
was the direct cause of decline of mortality was questioned.
Inspiringly, we found Ani could decrease both serum potassium
and mortality in rats with hyperkalemia by similar degrees to
those in crush syndrome. All these results indicated that Ani
could decrease on-site mortality in crush syndrome through
modest reduction (−10 ∼ −20%) of serum potassium with
no risk of hypokalemia, although not as markedly as expected.
Furthermore, the beneficial effect of Ani on serum potassium
was also mediated by activation of α7nAChR in mice with crush
syndrome, which indirectly proved the cause-effect relationship
between serum potassium and mortality in crush syndrome.
Moreover, extracellular potassium and glucose were also proved
to be reduced through activating α7nAChR but not other
nicotinic ACh receptors (blocked by hexamethonium) in cultured
myotubes.
Insulin can decrease serum potassium, accompanying
reduction of serum glucose. Enhancement of insulin sensitivity
may strengthen such effect on serum potassium. It has been
reported that chronic nicotine administration can reduce
insulin resistance in obese mice and enhance insulin sensitivity
in normal rats via α7nAChR (Wang et al., 2011; Xu et al.,
2012). Moreover, α7−/− mice exhibit insulin resistance (Wang
et al., 2011; Somm et al., 2014). Our results showed that blood
insulin and glucose levels were elevated in rats with crush
syndrome, which were reduced by Ani treatment with no risk of
hypoglycemia. The dropped insulin sensitivity was also enhanced
by Ani, represented as decreased HOMA-IR and increased
QUICKI. Furthermore, such effects were also mediated by
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FIGURE 7 | Continued
activation of α7nAChR, proved in mice with PNU, MLA, or
α7nAChR deficiency. Na/K-ATPase functions as a solute pump
that pumps sodium out of cells while pumping potassium into
cells. As reported, insulin increases potassium uptake through
FIGURE 7 | Continued
Influences of insulin signaling blocking on the effect of Ani on
extracellular K+ in C2C12 cells. C2C12 myotubes were pretreated for
1 h with HNMPA-(AM)3 (HNMPA, 200 µmol/L), LY 294002 (10 µmol/L),
rapamycin (200 nmol/L), stattic (10 µmol/L), or ouabain (2 mmol/L), and then
for 30 min with Ani (500 µg/ml) + ACh (100 µmol/L) prior to exposure to
KCl (5 mmol/L), and extracellular K+ and glucose levels were measured 6 h
later. Extracellular K+ and glucose in cultured myotubes were significantly
decreased by Ani + ACh. HNMPA (A,B), LY 294002 (C,D), and rapamycin
(E,F) attenuated such effects. Stattic (G,H) and ouabain (I,J) attenuated the
effect of Ani + ACh on extracellular K+ but not on glucose. N = 8 per group.
∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. control. #P < 0.05, ##P < 0.01,
###P < 0.001 vs. ACh + Ani. Power = 1.00 for (A–J).
FIGURE 8 | Proposed mechanism by which activation of α7nAChR
decreases on-site mortality in crush syndrome. Hex, hexamethonium;
HNMPA, HNMPA-(AM)3; InsR, insulin receptor; KO, knockout; mTOR,
mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase; STAT3,
signal transducer and activator of transcription 3.
activation of Na/K-ATPase (Chibalin et al., 2001; Al-Khalili
et al., 2004; Benziane and Chibalin, 2008; Clausen, 2010). In
our study, activation of Na/K-ATPase was enhanced by Ani
and ACh, but reduced by inhibition of tyrosine kinase on
insulin receptor with HNMPA-(AM)3. Besides HNMPA-(AM)3,
inhibition of phosphoinositide 3-kinase, mammalian target
of rapamycin, signal transducer and activator of transcription
3, and Na/K-ATPase with LY 294002, rapamycin, static, and
ouabain respectively could all decrease extracellular potassium.
All the results demonstrated that activation of α7nAChR could
increase insulin sensitivity to activate downstream signaling and
Na/K-ATPase, and to decrease serum potassium consequently.
We also examined the influence of Ani on hypovolemic shock
in rats with crush syndrome shortly after decompression. Ani
could alleviate hypotension through activation of α7nAChR, but
had no effect on heart rate. Such effect was proved in rats
with hemorrhagic shock, by elevation of blood pressure and
reduction of mortality (data not shown). Therefore, activation of
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α7nAChR could decrease on-site mortality in crush syndrome
through alleviation of both hyperkalemia and hypovolemic
shock. The antishock effect of Ani is mediated by cholinergic
anti-inflammatory pathway, besides the putative and non-
specific mechanisms to improve blood flow in microcirculation
(Poupko et al., 2007; Liu et al., 2009). Increasing evidences
prove that High mobility group box 1 (HMGB1), a
kind of damage-associated molecular pattern molecule,
can initiate and perpetuate a non-infectious inflammatory
response (Tsung et al., 2005; Rubartelli and Lotze, 2007;
Bald et al., 2014; Huang et al., 2015). We found that
HMGB1 was dramatically increased in crush syndrome,
which could be partially corrected by treatment with Ani.
However, neutralization of HMGB1 with its antibody had
no influence on the effect of Ani on on-site mortality
in mice with crush syndrome (data not shown). The
influence of Ani on proinflammatory cytokines in crush
syndrome and its relationship with mortality need further
investigations.
CONCLUSION
This study demonstrates that activation of α7nAChR could
decrease on-site mortality in crush syndrome based on
the decline of serum potassium through insulin signaling-
Na/K-ATPase pathway (Figure 8). Drugs targeting at
activation of α7nAChR, such as Ani, are encouraged for
on-site remedy of crush syndrome, which needs further
investigations.
Limitations
In the present study, on-site mortality in crush syndrome was
proved to be decreased by activation of α7nAChR through
decline of serum potassium. However, changes in the incidence of
cardiac arrest caused by hyperkalemia were not detected, which
need further investigation. Involvement of insulin sensitivity
and Na/K-ATPase in the reduction of on-site mortality in
crush syndrome by activation of α7nAChR was not proved by
corresponding inhibitors in vivo, considering the possibility that
the mortality may be increased by disorders in serum glucose and
energy supply.
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